Serum Phosphorus and Pill Burden Among Hemodialysis Patients Prescribed Sucroferric Oxyhydroxide: One-Year Follow-Up on a Contemporary Cohort
Open Access
- 1 April 2022
- journal article
- research article
- Published by Taylor & Francis in International Journal of Nephrology and Renovascular Disease
- Vol. ume 15, 139-149
Abstract
Purpose: In prior analyses of real-world cohorts of hemodialysis patients switched from one phosphate binder (PB) to sucroferric oxyhydroxide (SO), SO therapy has been associated with improvements in serum phosphorus (sP) and reductions in daily PB pill burden. To characterize how SO initiation patterns have changed over time, we examined the long-term effectiveness of SO in a contemporary (2018– 2019) cohort. Patients and Methods: Adult Fresenius Kidney Care hemodialysis patients first prescribed SO monotherapy as part of routine care between May 2018 and May 2019 (N = 1792) were followed for 1 year. All patients received a non-SO PB during a 91-day baseline period before SO prescription. Mean PB pills/day and laboratory parameters were compared before and during SO treatment. Results were divided into consecutive 91-day intervals (Q1–Q4) and analyzed using linear mixed-effects regression and Cochran’s Q test. These results were contrasted with findings from a historical (2014– 2015) cohort (N = 530). Results: The proportion of patients achieving sP ≤ 5.5 mg/dl increased after switching to SO (from 27.0% at baseline to 37.8%, 45.1%, 44.7%, and 44.0% at Q1, Q2, Q3, and Q4, respectively; P < 0.0001 for all). The mean daily PB pill burden decreased from a baseline of 7.7 to 4.4, 4.6, 4.8, and 4.9, respectively, across quarters (P < 0.0001 for all). Patients in the contemporary cohort had improved sP control (27.0% achieving sP ≤ 5.5 mg/dl vs 17.7%) and lower daily PB pill burden (mean 7.7 vs 8.5 pills/day) at baseline than those in the historical cohort. Overall use of active vitamin D was similar between cohorts, although higher use of oral active vitamin D (63.9% vs 15.7%) and lower use of IV active vitamin D lower (23.4% vs 74.2%) was observed in the contemporary cohort. Conclusion: Despite evolving treatment patterns, switching to SO resulted in improved sP control with fewer pills per day in this contemporary hemodialysis cohort.Keywords
This publication has 34 references indexed in Scilit:
- A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patientsKidney International, 2014
- Phosphate control in dialysisInternational Journal of Nephrology and Renovascular Disease, 2013
- Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysisNephrology Dialysis Transplantation, 2013
- Racial Differences in Clinical Use of Cinacalcet in a Large Population of Hemodialysis PatientsAmerican Journal of Nephrology, 2013
- Management of hyperphosphataemia in chronic kidney disease--challenges and solutionsClinical Kidney Journal, 2013
- Oral Phosphate Binders in Patients with Kidney FailureNew England Journal of Medicine, 2010
- The Case against Calcium-Based Phosphate BindersClinical Journal of the American Society of Nephrology, 2006
- A comparison of clinically useful phosphorus binders for patients with chronic kidney failureKidney International, 2004
- Mineral Metabolism, Mortality, and Morbidity in Maintenance HemodialysisJournal of the American Society of Nephrology, 2004
- Bone metabolism and disease in chronic kidney diseaseAmerican Journal of Kidney Diseases, 2003